Company announcement no. 6-2019
Birkerød, 25 April 2019
Minutes of annual general meeting 2019 in Virogates A/S, CVR-no 25 73 40 33 (“Virogates”).
Today, 25 April 2019, an annual general meeting was held in ViroGates at Comwell Holte, Kongevejen 495A, 2840 Holte. Reference is made to company announcement no. 4-2019 of 8 April 2019 setting out the agenda and complete proposals.
The following resolutions were passed:
For further information contact:
CEO Jakob Knudsen
Tel. (+45) 2113 1336, Email: jk@virogates.com
ViroGates A/S
CVR-nr. 25734033
Blokken 45, DK-340 Birkerød
www.virogates.com
Certified Advisor
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, Email: per.lonn@vhcorp.se
About ViroGates
ViroGates is an international medtech company headquartered in Denmark. ViroGates develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular to make a clinical decision on hospitalization or discharge of emergency patients, which can lead to better clinical decisions, faster discharge and optimization of healthcare resources. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, cancer, etc. The ViroGates test suPARnostic® measures the suPAR (Soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream, and with the suPARnostic® Quick Triage test, hospital staff will get answers in just 20 minutes. The prognostic value of suPARnostic® is validated by more than 500 clinical trials and studies which included more than 300,000 blood samples.
Attachment